Identifai Genetics

By taking a simple blood test from the mother-to-be, we can read the fetal DNA! No more risky, complicated and late invasive tests like amniocentesis - we are revolutionizing the way prenatal testing is done.

Compugen

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive AI/ML powered computational discovery platform (Unigen™) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen’s clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development is licensed to Gilead. In addition, the Company’s therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to address new mechanisms to activate the immune system against cancer. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen’s shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

Teiko.bio

Teiko.bio equips scientific and clinical teams with actionable intelligence at a cellular level. Pairing cutting-edge mass cytometry with a high-dimensional machine learning model, teiko.bio unlocks more information about individual immune characteristics to drive clinical insights.

noxgen biotech

At Noxgen Biotech, we believe in the power of biotechnology to shape a brighter future for all materializing transformative biotech solutions that empower and enhance lives. With a rich history of 10 years expertise in molecular diagnostics, phage research, genetics, biomedical supplies manufacturing and a wide spectrum of biotech projects, we're committed to driving innovation and improving the world's well-being. Our commitment extends beyond the laboratory. Focusing our efforts on Noxgen Labs, our laboratory coworking space, we create an innovation ecosystem in biotechnology. Targeted at researchers, scientists, entrepreneurs, early-stage startups, companies, and investors, we are ready to tackle current and future challenges through biotechnology. Additionally, our health-focused unit, Sendia, specializes in genetic testing, paving the way for personalized medicine. We catalyze positive change and shape a future where science meets impact.

Cytosens

Life Science Products, Distribution and Custom Services. We are committed to accelerating your science by providing a comprehensive suite of solutions. We are a team made of people having both national and international laboratory experience, and consolidated problem-solving skills; our main purpose is not only to provide customers with our products, but also with solutions, answering scientific and technical questions, as well as representing their constant reference point. Innovative Cytometry Tools, Molecular Cells applications and cellular devices and applications​ Our main purpose is supporting our customers with our solutions, answering scientific and technical questions, always tailoring the right solution for each need. In order to face the recent advances in research application, more and more focused on cellular analysis, we created an innovative company with a mission: gathering all the present and cutting edge technologies already available in other countries and bring them to the Italian market. With our sales network in continuous development and supported by our application specialists’ team, our goal is to become a Life Science Technology Hub where the most of scientists’, researchers’ and clinicians needs can be met.